ArticleEuropean journal of cancer (Oxford, England : 1990)2024

First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.

Filip Janku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.